Targeted Therapy (Antibody-Drug Conjugate)
22 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.
Targeted Therapy (Antibody-Drug Conjugate) (22)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Brentuximab Vedotin |
ADC | Hematologic | ||
|
Molecule
Brentuximab Vedotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
Enfortumab Vedotin |
ADC | Solid Tumour | ||
|
Molecule
Enfortumab Vedotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Polatuzumab Vedotin |
ADC | Hematologic | ||
|
Molecule
Polatuzumab Vedotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
Sacituzumab Govitecan |
ADC | Solid Tumour | ||
|
Molecule
Sacituzumab Govitecan
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Datopotamab Deruxtecan |
ADC | Solid Tumour | ||
|
Molecule
Datopotamab Deruxtecan
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Belantamab Mafodotin |
ADC | Hematologic | ||
|
Molecule
Belantamab Mafodotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
Cofetuzumab Pelidotin |
ADC | Solid Tumour | ||
|
Molecule
Cofetuzumab Pelidotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Depatuxizumab Mafodotin |
ADC | Solid Tumour | ||
|
Molecule
Depatuxizumab Mafodotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Farletuzumab Ecteribulin |
ADC | Solid Tumour | ||
|
Molecule
Farletuzumab Ecteribulin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Gemtuzumab Ozogamicin |
ADC | Hematologic | ||
|
Molecule
Gemtuzumab Ozogamicin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
Inotuzumab Ozogamicin |
ADC | Hematologic | ||
|
Molecule
Inotuzumab Ozogamicin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
Ladiratuzumab Vedotin |
ADC | Solid Tumour | ||
|
Molecule
Ladiratuzumab Vedotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Brentuximab VedotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
Enfortumab VedotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Polatuzumab VedotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
Sacituzumab GovitecanTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Datopotamab DeruxtecanTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Belantamab MafodotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
Cofetuzumab PelidotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Depatuxizumab MafodotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Farletuzumab EcteribulinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Gemtuzumab OzogamicinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
Inotuzumab OzogamicinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
Ladiratuzumab VedotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|